IBRX vs. BPMC, ROIV, RVMD, VRNA, BBIO, ELAN, GRFS, TGTX, TLX, and NUVL
Should you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Verona Pharma (VRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Grifols (GRFS), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.
ImmunityBio vs.
Blueprint Medicines (NASDAQ:BPMC) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.
Blueprint Medicines has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500.
Blueprint Medicines currently has a consensus target price of $129.35, indicating a potential upside of 1.08%. ImmunityBio has a consensus target price of $12.25, indicating a potential upside of 266.77%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Blueprint Medicines.
8.6% of ImmunityBio shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by company insiders. Comparatively, 76.8% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Blueprint Medicines had 28 more articles in the media than ImmunityBio. MarketBeat recorded 37 mentions for Blueprint Medicines and 9 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.54 beat Blueprint Medicines' score of 0.23 indicating that ImmunityBio is being referred to more favorably in the news media.
Blueprint Medicines has higher revenue and earnings than ImmunityBio. Blueprint Medicines is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.
Blueprint Medicines has a net margin of -13.19% compared to ImmunityBio's net margin of -8,016.83%. ImmunityBio's return on equity of 0.00% beat Blueprint Medicines' return on equity.
Blueprint Medicines received 526 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 66.99% of users gave Blueprint Medicines an outperform vote while only 57.14% of users gave ImmunityBio an outperform vote.
Summary
Blueprint Medicines and ImmunityBio tied by winning 9 of the 18 factors compared between the two stocks.
Get ImmunityBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunityBio Competitors List
Related Companies and Tools
This page (NASDAQ:IBRX) was last updated on 6/10/2025 by MarketBeat.com Staff
